230 related articles for article (PubMed ID: 15113912)
1. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Van Rompay KK; Singh RP; Pahar B; Sodora DL; Wingfield C; Lawson JR; Marthas ML; Bischofberger N
J Virol; 2004 May; 78(10):5324-37. PubMed ID: 15113912
[TBL] [Abstract][Full Text] [Related]
2. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Van Rompay KK; Trott KA; Jayashankar K; Geng Y; LaBranche CC; Johnson JA; Landucci G; Lipscomb J; Tarara RP; Canfield DR; Heneine W; Forthal DN; Montefiori D; Abel K
Retrovirology; 2012 Jul; 9():57. PubMed ID: 22805180
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
[TBL] [Abstract][Full Text] [Related]
4. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
[TBL] [Abstract][Full Text] [Related]
5. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Lifson JD; Piatak M; Cline AN; Rossio JL; Purcell J; Pandrea I; Bischofberger N; Blanchard J; Veazey RS
J Med Primatol; 2003 Aug; 32(4-5):201-10. PubMed ID: 14498980
[TBL] [Abstract][Full Text] [Related]
6. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Cherrington JM; Marthas ML; Lamy PD; Dailey PJ; Canfield DR; Tarara RP; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1999 Apr; 43(4):802-12. PubMed ID: 10103184
[TBL] [Abstract][Full Text] [Related]
7. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
Lifson JD; Rossio JL; Piatak M; Parks T; Li L; Kiser R; Coalter V; Fisher B; Flynn BM; Czajak S; Hirsch VM; Reimann KA; Schmitz JE; Ghrayeb J; Bischofberger N; Nowak MA; Desrosiers RC; Wodarz D
J Virol; 2001 Nov; 75(21):10187-99. PubMed ID: 11581387
[TBL] [Abstract][Full Text] [Related]
8. Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2.
Mattapallil JJ; Smit-McBride Z; Dailey P; Dandekar S
J Virol; 1999 Aug; 73(8):6661-9. PubMed ID: 10400763
[TBL] [Abstract][Full Text] [Related]
9. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
Kersh EN; Luo W; Adams DR; Mitchell J; Garcia-Lerma JG; Heneine W; Folks TM; Butera S; Otten RA
AIDS Res Hum Retroviruses; 2008 Apr; 24(4):543-6. PubMed ID: 18370590
[TBL] [Abstract][Full Text] [Related]
10. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Van Rompay KK; Singh RP; Brignolo LL; Lawson JR; Schmidt KA; Pahar B; Canfield DR; Tarara RP; Sodora DL; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):900-14. PubMed ID: 15220696
[TBL] [Abstract][Full Text] [Related]
11. Control of SIV rebound through structured treatment interruptions during early infection.
Lori F; Lewis MG; Xu J; Varga G; Zinn DE; Crabbs C; Wagner W; Greenhouse J; Silvera P; Yalley-Ogunro J; Tinelli C; Lisziewicz J
Science; 2000 Nov; 290(5496):1591-3. PubMed ID: 11090360
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Miller MD; Marthas ML; Margot NA; Dailey PJ; Canfield DR; Tarara RP; Cherrington JM; Aguirre NL; Bischofberger N; Pedersen NC
J Virol; 2000 Feb; 74(4):1767-74. PubMed ID: 10644348
[TBL] [Abstract][Full Text] [Related]
13. Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Kubo M; Nishimura Y; Shingai M; Lee W; Brenchley J; Lafont B; Buckler-White A; Igarashi T; Martin MA
J Virol; 2009 Jul; 83(14):7099-108. PubMed ID: 19420078
[TBL] [Abstract][Full Text] [Related]
14. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Van Rompay KK; Marthas ML; Lifson JD; Berardi CJ; Vasquez GM; Agatep E; Dehqanzada ZA; Cundy KC; Bischofberger N; Pedersen NC
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):761-73. PubMed ID: 9643376
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Rosenwirth B; ten Haaft P; Bogers WM; Nieuwenhuis IG; Niphuis H; Kuhn EM; Bischofberger N; Heeney JL; Uberla K
J Virol; 2000 Feb; 74(4):1704-11. PubMed ID: 10644340
[TBL] [Abstract][Full Text] [Related]
16. Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Van Rompay KK; Singh RP; Heneine W; Johnson JA; Montefiori DC; Bischofberger N; Marthas ML
J Virol; 2006 Jul; 80(13):6399-410. PubMed ID: 16775328
[TBL] [Abstract][Full Text] [Related]
17. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
Lifson JD; Rossio JL; Arnaout R; Li L; Parks TL; Schneider DK; Kiser RF; Coalter VJ; Walsh G; Imming RJ; Fisher B; Flynn BM; Bischofberger N; Piatak M; Hirsch VM; Nowak MA; Wodarz D
J Virol; 2000 Mar; 74(6):2584-93. PubMed ID: 10684272
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
Villinger F; Brice GT; Mayne AE; Bostik P; Mori K; June CH; Ansari AA
Blood; 2002 Jan; 99(2):590-9. PubMed ID: 11781243
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Shen Y; Shen L; Sehgal P; Zhou D; Simon M; Miller M; Enimi EA; Henckler B; Chalifoux L; Sehgal N; Gastron M; Letvin NL; Chen ZW
J Virol; 2001 Sep; 75(18):8690-6. PubMed ID: 11507214
[TBL] [Abstract][Full Text] [Related]
20. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
van Rompay KK; Dailey PJ; Tarara RP; Canfield DR; Aguirre NL; Cherrington JM; Lamy PD; Bischofberger N; Pedersen NC; Marthas ML
J Virol; 1999 Apr; 73(4):2947-55. PubMed ID: 10074144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
